Migraines are manifested by severe pain and headache that can last anywhere from four to seventy-two hours, accompanied by nausea, vomiting, and sensitivity to both light and sound.
Researcher Venkata Yellepeddi along with his colleagues from Roseman University of Health Sciences developed a preservative-free device-driven prochlorperazine nasal spray that could prove useful for compounding pharmacists specifically in the field of pain medicine.
Yellepeddi said that prochloperazine is a dopamine receptor antagonist that is widely used as an anti-nausea medication and comparative clinical studies have shown that prochloperazine provides better pain relief than other anti-migraine drugs such as sumatriptan, metoclopramide, and ketorolac.
Yellepeddi said that currently, there are no marketed nasal spray formulations of prochlorperazine available for the treatment of migraine and Prochlorperazine is only available in tablet form, which has delayed onset of action.
Researchers hypothesize that a nasal spray version of prochlorperazine will not only be effective, but fast acting and have better patient compliance overall.